Elanco Confirms NYSE Listing for Common Stock & Equity Units

Ticker: ELAN · Form: 8-K · Filed: Jan 8, 2024 · CIK: 1739104

Elanco Animal Health Inc 8-K Filing Summary
FieldDetail
CompanyElanco Animal Health Inc (ELAN)
Form Type8-K
Filed DateJan 8, 2024
Risk Levellow
Pages2
Reading Time2 min
Sentimentneutral

Complexity: simple

Sentiment: neutral

Topics: regulatory-filing, exchange-listing, corporate-governance

TL;DR

**Elanco's stock and equity units are still trading on the NYSE, business as usual.**

AI Summary

Elanco Animal Health Inc. filed an 8-K on January 8, 2024, to disclose that its Common Stock and 5.00% Tangible Equity Units are both registered on the New York Stock Exchange under the trading symbols ELAN and ELAT, respectively. This filing primarily serves to update the public record regarding its listed securities, confirming their active trading status. For investors, this matters because it reaffirms the liquidity and transparency of Elanco's publicly traded securities, ensuring they can be easily bought and sold on a major exchange.

Why It Matters

This filing confirms the continued listing of Elanco's securities on the NYSE, which is crucial for maintaining investor confidence and ensuring market liquidity.

Risk Assessment

Risk Level: low — This filing is purely administrative, confirming existing listings, and introduces no new financial or operational risks.

Analyst Insight

This filing is purely informational, confirming existing market conditions. A smart investor would note the continued listing on a major exchange, which supports liquidity, but would not base investment decisions solely on this administrative update.

Key Players & Entities

  • Elanco Animal Health Incorporated (company) — the registrant filing the 8-K
  • New York Stock Exchange (company) — the exchange where Elanco's securities are registered
  • ELAN (company) — trading symbol for Elanco's Common Stock
  • ELAT (company) — trading symbol for Elanco's 5.00% Tangible Equity Units

FAQ

What is the purpose of Elanco Animal Health Inc.'s 8-K filing dated January 8, 2024?

The 8-K filing by Elanco Animal Health Inc. on January 8, 2024, serves to disclose information under Regulation FD and Financial Statements and Exhibits, specifically confirming the registration of its Common Stock and 5.00% Tangible Equity Units on the New York Stock Exchange.

What are the trading symbols for Elanco Animal Health Inc.'s registered securities?

Elanco Animal Health Inc.'s Common Stock trades under the symbol ELAN, and its 5.00% Tangible Equity Units trade under the symbol ELAT, both on the New York Stock Exchange.

On what date was the earliest event reported in this 8-K filing?

The Date of Earliest Event Reported in this 8-K filing is January 8, 2024.

What is Elanco Animal Health Inc.'s business address as stated in the filing?

Elanco Animal Health Inc.'s business address is 2500 Innovation Way, Greenfield, Indiana 46140.

Is this 8-K filing intended to satisfy any other filing obligations?

Yes, the filing indicates it is intended to simultaneously satisfy filing obligations under Written communications pursuant to Rule 425 under the Securities Act, Soliciting material pursuant to Rule 14a-12 under the Exchange Act, Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act, and Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.

Filing Stats: 523 words · 2 min read · ~2 pages · Grade level 10.8 · Accepted 2024-01-08 17:00:27

Filing Documents

01

Item 7.01 Regulation FD. On January 9, 2024, Elanco Animal Health Incorporated (the "Company") will present at the 42 nd Annual J.P. Morgan Healthcare Conference (the "JPM Conference"). A copy of the Company's presentation is furnished as Exhibit 99.1. The information in this Item 7.01, including Exhibit 99.1 attached hereto, is being furnished and shall not be deemed "filed" for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended ("Exchange Act"), or otherwise subject to the liabilities of that Section and shall not be incorporated by reference into any registration statement or other document pursuant to the Securities Act of 1933, as amended, or the Exchange Act, except as otherwise expressly stated in such filing.

Financial Statements and Exhibits

Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Investor Presentation of Elanco Animal Health Incorporated at the JPM Conference. 104.1 Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Elanco Animal Health Incorporated Date: January 8, 2024 By: /s/ Todd Young Name: Todd Young Title: Executive Vice President and Chief Financial Officer

View Full Filing

View this 8-K filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.